Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

(2018) Dandan Chen et al.   CELL CYCLE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma

(2018) Manh-Cuong Vo et al.   Frontiers in Immunology

FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.

(2018) Aviva C Krauss et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

(2018) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

(2018) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression

(2017) Massimo Giuliani et al.   Oncotarget

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

(2016) Jacalyn Rosenblatt et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Immune Therapies in Multiple Myeloma

(2016) Shaji K. Kumar et al.   CLINICAL CANCER RESEARCH

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

(2016) Claudia Zelle-Rieser et al.   Journal of Hematology & Oncology

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

(2016) Claire F. Friedman et al.   JAMA Oncology

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study

(2015) H Suen et al.   LEUKEMIA

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies

(2015) T Dosani et al.   Blood Cancer Journal

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients

(2015) S Yousef et al.   Blood Cancer Journal

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

(2015) D. J. Chung et al.   Cancer Immunology Research

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

(2014) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

(2013) J. Rosenblatt et al.   CLINICAL CANCER RESEARCH

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

(2012) O. J. Finn   ANNALS OF ONCOLOGY

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology